INBP (Integrated Biopharma) 3-Month Share Buyback Ratio: 0.00% (As of Mar. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INBP Integrated Biopharma Inc INBP
36 GF Score
Price $0.19
GF Value $0.26
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Integrated Biopharma 3-Month Share Buyback Ratio?

Integrated Biopharma INBP +5.56% 36 3-Month Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Integrated Biopharma's current 3-Month Share Buyback Ratio was 0.00%.


Integrated Biopharma  (OTCPK:INBP) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Integrated Biopharma 3-Month Share Buyback Ratio Related Terms


INBP vs CIMG, BABB, PAVS: 3-Month Share Buyback Ratio Comparison

For the Packaged Foods subindustry, Integrated Biopharma's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrated Biopharma 3-Month Share Buyback Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Integrated Biopharma's 3-Month Share Buyback Ratio falls into.


INBP
36GF Score
Integrated Biopharma Inc INBP
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integrated Biopharma 3-Month Share Buyback Ratio Calculation

Integrated Biopharma's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2025 ) - Shares Outstanding (EOP) (Mar. 2026 )) / Shares Outstanding (EOP) (Dec. 2025 )
=(31.060 - 31.060) / 31.060
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of 0.00 mean?
Integrated Biopharma (INBP) has a 3-Month Share Buyback Ratio of 0.00 as of Mar. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Integrated Biopharma and its competitors.
Is Integrated Biopharma's 3-Month Share Buyback Ratio too high?
Integrated Biopharma's current 3-Month Share Buyback Ratio is 0.00. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's 3-Month Share Buyback Ratio compare to CIMG and BABB?
Integrated Biopharma's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Consumer Packaged Goods company?
A good 3-Month Share Buyback Ratio depends on the Consumer Packaged Goods industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Integrated Biopharma and its competitors. Integrated Biopharma's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.26, compared to a current price of $0.19 — trading 26.9% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current 3-Month Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integrated Biopharma (INBP) Overvalued in 2026?

Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued. The current stock price of $0.19 is trading 26.9% below its estimated GF Value™ of $0.26. GuruFocus considers Integrated Biopharma to be Modestly Undervalued.

Key valuation signals for INBP:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: $0.26 vs. price of $0.19 (26.9% below fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Integrated Biopharma Business Description

Address 225 Long Avenue, Building 15, Hillside, NJ, USA, 07205
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score

Get the complete analysis for INBP

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price
$0.26
GF Value